Clinical trial
Retifanlimab and Ruxolitinib In Solid Malignancies
NCT07219576
Study timeline
Study start (actual)2026-01-08Date precision: day
Registry last updated2026-01-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Carcinomaunresolved
Renal Cell Carcinomaunresolved
Interventions
RuxolitinibDRUG · verified · RxNorm: ruxolitinib
RetifanlimabDRUG · verified · RxNorm: retifanlimab
Sponsors & collaborators
University of California, San Diegolead sponsor
Incyte Corporationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07219576 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.